The incidence rate of BRCA1 vs. BRCA2 PCa and other cancers was investigated through the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), comprising data from 6902 men worldwide (33 countries). The gene discussed is BRCA2; the disease is posterior cortical atrophy.